Suven Pharma - Cohance Lifesciences Share Price

Overview
Recos
News
Analysis
Financials
Forecast
Technicals
Peers
Shareholdings
MF
F&O
Corp Actions
About

Suven Pharma - Cohance Lifesciences Share Price

405.85-7.95 (-1.93%)

Closed
As On: 19 Jun, 2026, 03:54 PM IST
As On: 19 Jun, 2026, 03:51 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

Open	410.00
High	412.30
Low	403.55
Prev Close	413.80
Volume	7,77,530
VWAP(₹)	406.09

Key Metrics

PE Ratio(x)	86.63
EPS - TTM(₹)	4.68
MCap(₹ Cr.)	15,526.49
MCap Rank	36
PB Ratio(x)	3.92
Div Yield(%)	-
Face Value(₹)	1.00
52W High(₹)	1,121.15
52W Low(₹)	266.70
MCap/Sales	5.09
Beta(1 Month)	-
BV/Share(₹)	105.44

Suven Pharma share price insights

Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 83.31% outperformed its 3 year CAGR of 18.22%. (Source: Consolidated Financials)
Sell Signal: Bears might roar again
Weekly stochastic crossover appeared on week ending Jun 19, 2026. Average price decline of -7.38% within 7 weeks of this signal in last 10 years.
Employee & Interest Expense
Company has spent 1.64% of its operating revenues towards interest expenses and 22.38% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)
Suven Pharma Share Price Update
Cohance Lifesciences Ltd. share price moved down by -1.93% from its previous close of Rs 413.80. Cohance Lifesciences Ltd. stock last traded price is 405.85
Share Price Value
Today/Current/Last 405.85407.75
Previous Day 413.80414.00

Share Price	Value
Today/Current/Last	405.85407.75
Previous Day	413.80414.00

Found Insights useful?

Suven Pharma Share Price Returns

1 Day	-1.93%
1 Month	-5.25%
3 Months	35.62%
1 Year	-59.03%
3 Years	-16.55%
5 Years	-15.38%

Suven Pharma Share Recommendations

Mean recosCurrent

HOLD

8 Analysts

Strong
SellSellHoldBuyStrong
Buy

Analyst Trends

Ratings	Current	1W Ago	1M Ago	3M Ago
Strong Buy	1	1	2	2
Buy	2	2	2	3
Hold	1	1	1	3
Sell	2	2	2	-
Strong Sell	2	2	1	-
# Analysts	8	8	8	8

Recent Recos

Target₹1400
OrganizationICICI Securities
BUY

Target₹602
OrganizationGeojit Financial Services
ACCUMULATE

Target₹600
OrganizationICICI Direct
BUY

View all Stock Recommendations

News & Analysis

View all Suven Pharma Share News & Announcements

Financials

Income (P&L)

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	617.28	550.71	571.17	563.48	412.59
Total Income Growth (%)	12.09	-3.58	1.36	36.57	27.79
Total Expenses	588.18	501.00	478.64	490.54	355.24
Total Expenses Growth (%)	17.40	4.67	-2.43	38.09	69.32
EBIT	29.10	49.71	92.53	72.94	57.35
EBIT Growth (%)	-41.46	-46.28	26.86	27.18	-49.27
Profit after Tax (PAT)	19.55	36.72	74.08	48.88	42.01
PAT Growth (%)	-46.76	-50.43	51.55	16.35	-49.31
EBIT Margin (%)	4.71	9.03	16.20	12.94	13.90
Net Profit Margin (%)	3.17	6.67	12.97	8.67	10.18
Basic EPS (₹)	0.51	0.96	1.94	1.28	1.65

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	566.76	487.70	524.09	496.68	336.80
Total Income Growth (%)	16.21	-6.94	5.52	47.47	15.91
Total Expenses	505.15	417.02	398.13	418.84	278.18
Total Expenses Growth (%)	21.13	4.74	-4.94	50.56	60.45
EBIT	61.61	70.68	125.96	77.84	58.62
EBIT Growth (%)	-12.83	-43.89	61.82	32.79	-49.98
Profit after Tax (PAT)	34.56	47.29	94.29	52.57	44.34
PAT Growth (%)	-26.92	-49.85	79.36	18.56	-48.65
EBIT Margin (%)	10.87	14.49	24.03	15.67	17.40
Net Profit Margin (%)	6.10	9.70	17.99	10.58	13.17
Basic EPS (₹)	0.90	1.24	2.46	1.38	1.74

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	2,302.64	1,256.14	1,113.26	1,386.69	1,412.60
Total Revenue Growth (%)	83.31	12.83	-19.72	-1.83	37.96
Total Expenses	2,066.13	912.22	707.59	826.96	786.12
Total Expenses Growth (%)	126.49	28.92	-14.44	5.19	28.87
Profit after Tax (PAT)	179.23	267.87	300.28	411.29	453.80
PAT Growth (%)	-33.09	-10.79	-26.99	-9.37	25.24
Operating Profit Margin (%)	12.06	29.74	39.29	42.16	47.92
Net Profit Margin (%)	7.90	22.36	28.56	30.68	34.37
Basic EPS (₹)	4.69	10.52	11.80	16.16	17.83

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	2,075.23	1,147.49	1,080.09	1,374.63	1,508.01
Total Revenue Growth (%)	80.85	6.24	-21.43	-8.84	47.27
Total Expenses	1,732.13	796.14	671.31	795.24	785.56
Total Expenses Growth (%)	117.57	18.59	-15.58	1.23	28.79
Profit after Tax (PAT)	228.71	271.71	304.82	432.60	558.10
PAT Growth (%)	-15.83	-10.86	-29.54	-22.49	80.82
Operating Profit Margin (%)	18.00	32.86	40.60	43.96	55.19
Net Profit Margin (%)	11.26	24.84	29.73	32.52	42.27
Basic EPS (₹)	5.98	10.67	11.97	16.99	21.92

All figures in Rs Cr, unless mentioned otherwise

Insights

Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 83.31% outperformed its 3 year CAGR of 18.22%. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent 1.64% of its operating revenues towards interest expenses and 22.38% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

View Details

Balance Sheet

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	5,729.64	3,031.75	2,254.09	1,965.74	1,829.59
Total Assets Growth (%)	88.99	34.50	14.67	7.44	24.08
Total Liabilities	1,695.81	1,191.11	203.42	230.56	302.41
Total Liabilities Growth (%)	42.37	485.53	-11.77	-23.76	2.98
Total Equity	4,033.83	1,840.64	2,050.66	1,735.18	1,527.18
Total Equity Growth (%)	119.15	-10.24	18.18	13.62	29.33
Current Ratio (x)	2.83	2.43	11.82	6.37	5.36
Total Debt to Equity (x)	0.04	0.05	0.02	0.04	0.06
Contingent Liabilities	0.00	48.41	58.55	40.43	29.38

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	5,113.20	2,587.81	2,240.72	1,958.33	1,804.89
Total Assets Growth (%)	97.59	15.49	14.42	8.50	32.83
Total Liabilities	633.09	272.26	184.82	208.95	284.19
Total Liabilities Growth (%)	132.53	47.31	-11.55	-26.48	-3.22
Total Equity	4,480.11	2,315.55	2,055.90	1,749.38	1,520.69
Total Equity Growth (%)	93.48	12.63	17.52	15.04	42.76
Current Ratio (x)	3.31	3.32	11.47	6.19	5.31
Total Debt to Equity (x)	0.02	0.03	0.02	0.04	0.06
Contingent Liabilities	0.00	48.41	56.30	190.84	29.38

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	368.32	288.16	358.48	450.91	330.00
Net Cash used in Investing Activities	-254.57	-255.30	-362.25	-194.84	-136.21
Net Cash flow from Financing Activities	-165.15	3.32	-13.80	-235.83	-156.41
Net Cash Flow	-47.51	38.17	-17.57	20.24	37.38
Closing Cash & Cash Equivalent	49.14	85.40	47.23	64.80	44.56
Closing Cash & Cash Equivalent Growth (%)	-42.46	80.81	-27.12	45.42	520.48
Total Debt/ CFO (x)	0.46	0.27	0.11	0.16	0.29

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	389.57	301.03	370.65	484.17	269.89
Net Cash used in Investing Activities	-204.29	-320.94	-381.58	-235.57	-90.36
Net Cash flow from Financing Activities	-202.78	20.81	-13.78	-235.79	-156.41
Net Cash Flow	-17.50	0.90	-24.71	12.81	23.12
Closing Cash & Cash Equivalent	13.11	19.36	18.31	43.02	30.21
Closing Cash & Cash Equivalent Growth (%)	-32.28	5.71	-57.43	42.41	325.85
Total Debt/ CFO (x)	0.24	0.23	0.10	0.14	0.35

All figures in Rs Cr, unless mentioned otherwise

Insights

Decrease in Cash from Investing
Company has used Rs 254.57 cr for investing activities which is an YoY decrease of 0.29%. (Source: Consolidated Financials)

View Details

Ratios

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	4.58	15.78	14.64	23.70	29.71
Return on Capital Employed (%)	5.38	13.36	19.24	31.27	39.07
Return on Assets (%)	3.12	8.83	13.32	20.92	24.80
Interest Coverage Ratio (x)	12.38	35.12	62.77	112.74	107.82
Asset Turnover Ratio (x)	0.52	0.45	0.50	0.71	0.81
Price to Earnings (x)	64.52	111.11	57.47	29.33	34.72
Price to Book (x)	2.95	17.40	8.40	6.93	10.30
EV/EBITDA (x)	25.56	68.38	36.80	19.64	23.49
EBITDA Margin (%)	20.32	36.21	44.48	45.72	50.88

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	5.10	11.73	14.82	24.72	36.70
Return on Capital Employed (%)	7.93	15.13	19.49	32.41	45.65
Return on Assets (%)	4.47	10.49	13.60	22.09	30.92
Interest Coverage Ratio (x)	22.22	52.07	62.61	116.41	123.22
Asset Turnover Ratio (x)	0.53	0.45	0.49	0.71	0.83
Price to Earnings (x)	50.51	108.70	56.82	27.86	28.25
Price to Book (x)	2.58	12.75	8.38	6.88	10.34
EV/EBITDA (x)	23.29	71.00	37.08	19.21	20.57
EBITDA Margin (%)	24.58	38.09	45.36	47.18	58.15

Found Financials useful?

Share Price Forecast

Exclusively for ETPrime

REVENUE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
EARNINGS
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
PRICE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP

Technicals

Buy/Sell Signals
Stochastic Crossover
Bearish signal on weekly chart
Appeared on: 19 Jun 2026
Region: Equlibrium
Last Signal 22 May 2026 (Loss 0.00%)
Average price decline of -7.38% within 7 weeks of Bearish signal in last 10 years
50 Day EMA Crossover
Bearish signal on daily chart
Appeared on: 18 Jun 2026
50D EMA: 415.91
Last Signal 17 Sep 2025 (Loss -11.42%)
Average price decline of -5.29% within 30 days of Bearish signal in last 5 years
5 Day EMA Crossover
Bearish signal on daily chart
Appeared on: 17 Jun 2026
5D EMA: 427.65
Last Signal 11 Jun 2026 (Loss -0.18%)
Average price decline of -2.81% within 7 days of Bearish signal in last 5 years
10 Day EMA Crossover
Bearish signal on daily chart
Appeared on: 17 Jun 2026
10D EMA: 428.10
Last Signal 11 Jun 2026 (Loss -0.18%)
Average price decline of -2.79% within 7 days of Bearish signal in last 5 years
14 Day EMA Crossover
Bearish signal on daily chart
Appeared on: 17 Jun 2026
14D EMA: 428.65
Last Signal 11 Jun 2026 (Loss -0.18%)
Average price decline of -2.89% within 7 days of Bearish signal in last 5 years
20 Day EMA Crossover
Bearish signal on daily chart
Appeared on: 17 Jun 2026
20D EMA: 428.55
Last Signal 11 Jun 2026 (Loss -0.18%)
Average price decline of -3.00% within 7 days of Bearish signal in last 5 years
Price Analysis
45%
Positive Movement
since 1st Jan 2005
on basis
54%
Negative Movement
since 1st Jan 2005
on basis
Exclude
Global Meltdown1st Jan 2008 to 10th Nov 2008
Covid Crisis1st Feb 2020 to 31st Mar 2020
Pivot Levels
R1 410.92 Pivot
407.23
S1 402.17
R2 415.98 S2 398.48
R3 424.73 S3 389.73
Average True Range
5 Days 14 Days 28 Days
15.21 17.43 19.64

5 Days	14 Days	28 Days
15.21	17.43	19.64

Found Technicals useful?

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Suven Pharma	86.63	3.85	4.58	5.38	3.12	18.22	12.06	6.61	4.69	2.83	0.04	0.46
Eris Lifesciences	32.39	5.15	15.87	16.04	8.41	22.50	27.10	20.68	45.33	0.74	0.59	4.29
Granules India	32.77	3.83	11.70	16.15	7.70	5.91	16.94	11.08	24.47	1.80	0.26	1.69
Caplin Point	29.68	5.24	17.87	21.95	15.85	14.62	36.74	29.70	84.36	6.70	0.00	0.00
OneSource Specialty	-249.83	3.16	-1.26	0.59	-0.89	222.32	2.82	-5.19	-6.44	0.99	0.22	149.75
Add More

Annual Ratios (%)

Choose from Peers

Syngene Int.
Aarti Inds
Natco Pharma
Jubilant Life
Alembic Pharma

Choose from Stocks

Stock Performance

CHART
TABLE

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Suven Pharma Stock Performance	-1.93	-8.84	12.36	32.89	-62.25	-14.44	-22.07
Eris Lifesciences Stock Performance	1.25	5.42	5.26	7.90	-3.82	133.07	104.37
Granules India Stock Performance	0.62	7.02	17.84	31.36	51.94	184.80	143.62
Caplin Point Stock Performance	6.11	23.70	43.16	47.95	11.15	257.59	324.68
OneSource Specialty Stock Performance	-2.58	-11.61	3.07	26.69	-4.18	0.00	0.00
Add More

Shareholding Pattern

Total Shareholdings
Category No. of Shares Percentage % Change QoQ
Promoters 21,99,30,170 57.49 % 0.00
Pledge 0 0.00 % 0.00
FII 2,14,03,157 5.59 % -0.41
DII 8,33,53,843 21.79 % 0.21
MF 7,10,37,605 18.57 % 1.21
Others 5,78,79,970 15.12 % 0.19
QoQ Change
Category Mar 2026 Dec 2025 Sep 2025 Jun 2025
Promoters 57.49 57.49 57.49 66.41
Pledge 0.00 0.00 0.00 0.00
FII 5.59 6.01 6.51 7.23
DII 21.79 21.57 20.81 11.40
Mutual Funds 18.57 17.36 16.49 8.90
Others 15.12 14.93 15.18 14.95

Category	No. of Shares	Percentage	% Change QoQ
Promoters	21,99,30,170	57.49 %	0.00
Pledge	0	0.00 %	0.00
FII	2,14,03,157	5.59 %	-0.41
DII	8,33,53,843	21.79 %	0.21
MF	7,10,37,605	18.57 %	1.21
Others	5,78,79,970	15.12 %	0.19

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	57.49	57.49	57.49	66.41
Pledge	0.00	0.00	0.00	0.00
FII	5.59	6.01	6.51	7.23
DII	21.79	21.57	20.81	11.40
Mutual Funds	18.57	17.36	16.49	8.90
Others	15.12	14.93	15.18	14.95

Mutual Funds Ownership

MF Ownership as on 31 May 2026

ICICI Pru Pharma Healthcare and Diagnostics (P.H.D) Direct-G
Equity: Sectoral-Pharma
4
- 282.16
  Amount Invested (in Cr.)
- 4.37211709%
  % of AUM
- 6.82
  % Change (MoM basis)
SBI Multi Asset Allocation Direct-G
Hybrid: Multi Asset Allocation
4
- 224.38
  Amount Invested (in Cr.)
- 1.22680193%
  % of AUM
- 160.00
  % Change (MoM basis)
HDFC Balanced Advantage Direct-G
Hybrid: Dynamic Asset Allocation
5
- 178.79
  Amount Invested (in Cr.)
- 0.17%
  % of AUM
- 0.00
  % Change (MoM basis)

View all Mutual Fund Schemes

Suven Pharma Top Searches

Corporate Actions

Recent
Board Meeting
Quarterly Results
Dec 29, 2025
General Meeting
-
Dec 23, 2025
Board Meeting
Quarterly Results
Sep 29, 2025

Board Meetings

Announced on	Meeting on
Dec 29, 2025	Feb 12, 2026
Quarterly Results
Sep 29, 2025	Nov 12, 2025
Quarterly Results
Jun 27, 2025	Aug 13, 2025
Quarterly Results
Mar 26, 2025	May 28, 2025
Audited Results
Dec 27, 2024	Feb 12, 2025
Quarterly Results

Dividends
Announced on Ex-Date Dividend%
Aug 30, 2022 Sep 09, 2022 500%
Aug 29, 2022 Sep 09, 2022 100%
May 03, 2022 May 13, 2022 100%
May 02, 2022 May 13, 2022 100%
Feb 02, 2022 Feb 15, 2022 200%
Bonus
Announced on Ex-Date
Aug 17, 2020 Sep 25, 2020
Bonus Ratio: 1 share(s) for every 1 shares held
Splits
No Data Available
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
Dec 23, 2025 Jan 23, 2026
-
Sep 16, 2025 Sep 19, 2025
-
Nov 21, 2024 Dec 19, 2024
-
Oct 28, 2024 Nov 28, 2024
-
Jul 15, 2024 -
Book closure from Aug 7, 2024 to Aug 9, 2024

Announced on	Ex-Date	Dividend%
Aug 30, 2022	Sep 09, 2022	500%
Aug 29, 2022	Sep 09, 2022	100%
May 03, 2022	May 13, 2022	100%
May 02, 2022	May 13, 2022	100%
Feb 02, 2022	Feb 15, 2022	200%

Announced on	Ex-Date
Aug 17, 2020	Sep 25, 2020
Bonus Ratio: 1 share(s) for every 1 shares held

Announced on	Meeting on
Dec 23, 2025	Jan 23, 2026
-
Sep 16, 2025	Sep 19, 2025
-
Nov 21, 2024	Dec 19, 2024
-
Oct 28, 2024	Nov 28, 2024
-
Jul 15, 2024	-
Book closure from Aug 7, 2024 to Aug 9, 2024

About Suven Pharma

Cohance Lifesciences Ltd., incorporated in the year 2018, is a Small Cap company (having a market cap of Rs 15,526.49 Crore) operating in Pharmaceuticals sector.

Cohance Lifesciences Ltd. key Products/Revenue Segments include Pharmaceuticals, Export Incentives, Sale of services and Scrap for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 617.28 Crore, up 12.09 % from last quarter Total Income of Rs 550.71 Crore and up 49.61 % from last year same quarter Total Income of Rs 412.59 Crore. Company has reported net profit after tax of Rs 8.31 Crore in latest quarter.

The company’s top management includes Mr.Vivek Sharma, Dr.V Prasada Raju, Dr.Sudhir Kumar Singh, Mr.Pankaj Patwari, Ms.Shweta Jalan, Mr.Vinod Padikkal, Mr.Jai Shankar Krishnan, Mr.K G Ananthakrishnan, Ms.Matangi Gowrishankar, Mr.U B Pravin Rao, Mr.Vinod Rao, Mr.Himanshu Agarwal, Mr.Kundan Kumar Jha. Company has Karvy & Co. as its auditors. As on 31-03-2026, the company has a total of 38.26 Crore shares outstanding.

Suven Pharma Share Price Today is Rs. 405.85. On previous day, the Suven Pharma Share Price (NSE) closed at Rs. 413.8, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 57.49% of the stake in Suven Pharma shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Suven Pharma stocks was 5.59% as compared to 6.01% in Dec 2025 with decrease of 0.42%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 21.79% as compared to 21.57% in Dec 2025 with increase of 0.22%. Out of the total DII holdings in Suven Pharma shares 18.57% was held by mutual funds. The rest including public held is 15.13%. Suven Pharma stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Suven Pharma Dividend: Ever since 2018, Suven Pharma dividends has been paid out around 8 times. As on 19 Jun, 2026, 03:54 PM IST, The overall dividend yield for Suven Pharma stands at 0.0%. The last dividend paid was on September 9, 2022 (Rs. 1.0). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 4.68.

Suven Pharma Bonus: The most recent bonus issue had been in year September 25, 2020 around 5 years ago at 1 : 1 ratio. The first bonus issue was announced in Aug 2020.

Stock Forecast:
After showing 617.28 Cr. of sales and 12.09% of quarterly net profit, there have been multiple ups and downs in the Suven Pharma stock prices in the past few weeks. For example, Suven Pharma stock price on 12th of June 2026 was around Rs. 426.95. Suven Pharma share price now stands at an average of Rs. 405.85. Judging by last week's performance, stock is in down trend.

Suven Pharma has a median target price of Rs. 530.14 in 12 months by 7 analysts. They have provided a high estimate of Rs. 1150.0 and low estimate of Rs. 300.0 for Suven Pharma share.

Historical Prices and Performance:
Suven Pharma,incorporated in 2018 is a Mid Cap company (with a market cap of Rs. 15526.49) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Suven Pharma stock was 4.58%, 15.78%, 14.64%, 23.7% and 29.71% respectively.
The Suven Pharma share gave a 3 year return of -16.55% as compared to Nifty 50 which gave a return of 28.03%.
Suven Pharma announced 100.0% final dividend on September 9, 2022.

Key Metrics:
PE Ratio of Suven Pharma is 86.63
Prices/Sales Ratio of Suven Pharma is 5.09
Price/Book Ratio of Suven Pharma is 3.85

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Suven Pharma,major competitors and peers include Eris Lifesciences, Granules India, Caplin Point and OneSource Specialty. As of Dec 2025, the dividend yield of Suven Pharma stands at 0.0% while Eris Lifesciences, Granules India, Caplin Point and OneSource Specialty stand at 0.5%, 0.22%, 0.16% and 0.0% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 86.63 and 3.85 respectively.

Recommendations:
The current total number of analysts covering the stock stands at 8, Three months ago this number stood at 8. Out of total, 1 analyst have a'Strong Buy' reco, 2 analyst have a'Buy' reco, 1 analyst have a'Hold' reco, 2 analyst have a'Sell' reco.

Mean recommendations by 8 analyst stand at'Buy'.

Leadership of Suven Pharma :
Himanshu Agarwal is Chief Financial Officer
Sudhir Kumar Singh is Chief Executive Officer
Gaurav Bahadur is Chief Human Resource Officer
Kundan Kumar Jha is Head - Legal & Co. Secretary
Vivek Sharma is Executive Chairman
V Prasada Raju is Managing Director
Pankaj Patwari is Non Executive Director
Shweta Jalan is Non Executive Director
Vinod Padikkal is Non Executive Director
Vinod Rao is Independent Director
K G Ananthakrishnan is Independent Director
U B Pravin Rao is Independent Director
Matangi Gowrishankar is Independent Director
Jai Shankar Krishnan is Independent Director

Industry

Pharma - Indian

Key Indices Listed On

Nifty 500, BSE 500, Nifty MNC, BSE 250 SmallCap Index, BSE SmallCap

Address

215 Atrium, C Wing, 8th Floor,819-821, Andheri Kurla Road,Mumbai, Maharashtra - 400093

Contact

info@suvenpharm.com

http://www.suvenpharm.com

Executive Leadership

Vivek Sharma

Executive Chairman

V Prasada Raju

Managing Director

Sudhir Kumar Singh

Chief Executive Officer

Pankaj Patwari

Non Executive Director

Auditors

Walker Chandiok & Co. LLP

Karvy & Co.

FAQs about Suven Pharma share

1. What's Suven Pharma share price today and what are Suven Pharma share returns ?
Suven Pharma share price is Rs 405.85 as on 19 Jun, 2026, 03:54 PM IST. Suven Pharma share price is down by 1.93% based on previous share price of Rs 425.15. Suven Pharma share price trend:
- Last 12 Months: Suven Pharma share price moved down 59.03%
- Last 3 Years: Suven Pharma Share price moved down by 16.55%
2. What are the returns for Suven Pharma share?
Return Performance of Suven Pharma Shares:
- 1 Week: Suven Pharma share price moved down by 4.94%
3. What has been highest price of Suven Pharma share in last 52 weeks?
52 Week high of Suven Pharma share is Rs 1,121.15 while 52 week low is Rs 266.70
4. What's the market capitalization of Suven Pharma ?
Within the Pharmaceuticals sector, Suven Pharma stock has a market cap rank of 36. Suven Pharma has a market cap of Rs 15,526.49 Cr.
5. What is the PE & PB ratio of Suven Pharma ?
The PE ratio of Suven Pharma stands at 88.33, while the PB ratio is 3.92.

Top Gainers

As on 03:57 PM | 19 Jun 2026

Ather Energy

971.70

657.90 (209.66%)

Netweb Technologies

5,060.90

3254.10 (180.10%)

Syrma SGS Technology

1,334.00

805.00 (152.17%)

GE T&D India

5,533.50

3224.90 (139.69%)

HFCL

209.61

121.58 (138.11%)

Top Losers

As on 03:59 PM | 19 Jun 2026

Tata Investment

691.00

-6193.00 (-89.96%)

Angel One

353.70

-2663.90 (-88.28%)

Kotak Bank

399.25

-1727.55 (-81.23%)

CAMS

823.15

-3249.55 (-79.79%)

Authum Investment

543.80

-1954.00 (-78.23%)

Midcap stocks
Smallcap stocks
Largecap stocks
Sensex
Nifty
NSE
BSE
MCX Live

More from Markets

IPO
Stock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list

Trending in Markets

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.

Suven Pharma - Cohance Lifesciences Share Price

Key Metrics

Suven Pharma share price insights

Suven Pharma Share Price Returns

Suven Pharma Share Recommendations

News & Analysis

Financials

Share Price Forecast

Technicals

Peer Comparison

Shareholding Pattern

Mutual Funds Ownership

ICICI Pru Pharma Healthcare and Diagnostics (P.H.D) Direct-G

SBI Multi Asset Allocation Direct-G

HDFC Balanced Advantage Direct-G

Suven Pharma Top Searches

Corporate Actions

About Suven Pharma

Executive Leadership

Auditors

FAQs about Suven Pharma share

Top Gainers

Top Losers

Equity Quick Links

More from Markets

Trending in Markets

Browse Companies

Popular Categories

Hot on Web

In Case you missed it

Top Searched Companies

Latest News

PE Ratio(x)	87.03
EPS - TTM(₹)	4.68
MCap(₹ Cr.)	15,599.18
MCap Rank	36
PB Ratio(x)	3.94
Div Yield(%)	-
Face Value(₹)	1.00
52W High(₹)	1,121.15
52W Low(₹)	267.85
MCap/Sales	5.09
Beta(1 Month)	-
BV/Share(₹)	105.44

1 Day	-1.5%
1 Month	-5.05%
3 Months	36.23%
1 Year	-58.79%
3 Years	-16.18%
5 Years	-14.95%

R1	410.92	Pivot 407.23	S1	402.17
R2	415.98		S2	398.48
R3	424.73		S3	389.73